# CLEAR (NCT02811861)

> Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus pembrolizumab; lenvatinib plus everolimus
- Indication: first-line advanced renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02811861
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eisai Inc.
- Conditions: Renal Cell Carcinoma
- Interventions: Lenvatinib; Everolimus; Pembrolizumab; Sunitinib
- Enrollment: 1069
- Primary outcome: Progression-free Survival (PFS) by Independent Imaging Review (IIR)

## Indexed commentary on CLEAR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=clear-nct02811861